Saturday 17 October 2026
Export MNPR’s income statement to Excel — free account
Monopar Therapeutics Inc.
MNPR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 77.1% and free cash flow fell 201.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
69.27
2.53
−3.52%
Follow MNPR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.15 | 29.28 | 32.48 |
Net Debt/EBITDA |
8.06 | 3.72 | 0.82 | 1.25 | 2.22 | 2.57 | 3.06 | 2.07 | 0.54 | 1.74 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.89 | 0.41 | 0.94 | 0.69 | 0.80 | 0.74 | 0.71 | 0.83 | 0.16 | 1.01 |
Capex/Depreciation |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Interest Coverage |
— | — | — | — | — | — | — | — | — | (331.11) |
| (14.22%) | (51.42%) | (107.19%) | (72.44%) | (52.57%) | (44.52%) | (43.23%) | (39.04%) | (265.94%) | (19.05%) | |
| (13.65%) | (46.09%) | (81.68%) | (62.32%) | (48.69%) | (41.72%) | (40.88%) | (37.43%) | (258.13%) | (18.49%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (8,132.57%) | (1,627.75%) | 0.00% |
Return on Tangible Assets |
(9.96%) | (28.32%) | (150.71%) | (104.77%) | (48.06%) | (40.35%) | (33.78%) | (47.10%) | (187.71%) | (58.38%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(1.65) | (1.69) | (2.84) | (2.84) | (2.93) | (2.13) | (1.62) | (1.44) | (1.50) | (0.11) |
Cash per Share |
18.94 | 15.89 | 2.63 | 5.16 | 8.14 | 7.64 | 7.09 | 3.71 | 5.11 | 0.20 |
Shareholders Equity per Share |
18.60 | 14.52 | 2.02 | 3.97 | 7.59 | 7.16 | 6.77 | 3.72 | 5.48 | 0.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
18.60 | 14.52 | 2.02 | 3.97 | 7.59 | 7.16 | 6.77 | 3.72 | 5.48 | 0.27 |
Free Cash Flow |
(12.20) | (6.40) | (7.86) | (7.23) | (7.32) | (4.66) | (3.02) | (2.68) | (2.63) | (1.19) |
Working Capital |
137.73 | 55.04 | 5.58 | 10.04 | 18.94 | 15.62 | 12.51 | 6.85 | 8.82 | 2.03 |
Net Current Asset Value |
137.57 | 55.04 | 5.58 | 10.03 | 18.94 | 15.62 | 12.51 | 6.85 | 8.82 | 2.03 |
| Other line items | ||||||||||
Quick Ratio |
51.33 | 11.46 | 4.13 | 4.19 | 12.85 | 14.22 | 18.25 | 17.25 | 28.80 | 32.13 |
Depreciation/Fixed assets |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
Cash ROIC |
(4.39%) | (5.56%) | (61.14%) | (31.15%) | (18.65%) | (14.38%) | (11.68%) | (19.41%) | (14.13%) | (24.36%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.65) | (1.69) | (2.84) | (2.84) | (2.93) | (2.13) | (1.62) | (1.44) | (1.50) | (0.11) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
2.49 | 2.01 | 2.44 | 2.35 | 1.38 | 0.95 | 0.56 | 0.36 | 0.19 | 0.19 |
Average Assets |
100.50 | 33.82 | 10.29 | 16.87 | 18.70 | 15.11 | 10.34 | 8.62 | 6.41 | 6.41 |
Average Common Equity |
96.43 | 30.31 | 7.84 | 14.52 | 17.32 | 14.16 | 9.77 | 8.27 | 6.23 | 6.23 |
Columns are period end dates